Denenicokin

Drug Profile

Denenicokin

Alternative Names: BMS-982470; IL-21; Interleukin 21 - ZymoGenetics; rIL-21

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer National Cancer Institute (Canada); ZymoGenetics
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma; Non-Hodgkin's lymphoma; Renal cancer; Solid tumours
  • Discontinued Viral infections

Most Recent Events

  • 01 Dec 2014 Bristol-Myers Squibb completes a phase I trial for Solid tumours in USA (NCT01629758)
  • 01 Jun 2014 Bristol-Myers Squibb completes a phase I trial in Malignant melanoma (Combination therapy, Late stage disease) in USA and Puerto Rico (NCT01489059)
  • 01 Jul 2012 Phase-I clinical trials in Solid tumours (late-stage disease, combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top